New treatment for diabetic foot ulcers using nanoparticles and microRNA
A Novel Anti-inflammatoryand Anti-oxidant Therapy for Treating Non-healing Diabetic Foot Ulcers
This study is testing a new treatment to help heal diabetic foot ulcers faster by using a special injection that targets inflammation and stress in the body, and it's designed for people with diabetes who are dealing with these painful wounds.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ceria Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Tucson, UNITED STATES) |
| Project ID | NIH-11011333 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapy to improve healing in diabetic foot ulcers, which are a common and serious complication of diabetes. The approach involves using cerium oxide nanoparticles combined with a microRNA mimic that targets inflammation and oxidative stress, both of which hinder wound healing. The treatment is administered through a single intradermal injection, aiming to reduce inflammation and promote faster healing of the ulcers. Patients will be monitored for improvements in wound healing and overall recovery.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with non-healing diabetic foot ulcers.
Not a fit: Patients who do not have diabetic foot ulcers or those with other unrelated chronic wounds may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly enhance the healing process for diabetic foot ulcers, potentially reducing the need for amputations.
How similar studies have performed: Other research has shown promise in using nanoparticles and microRNA therapies for wound healing, indicating a potential for success with this novel approach.
Where this research is happening
Tucson, UNITED STATES
- Ceria Therapeutics, INC. — Tucson, United States (Active)
Researchers
- Principal investigator: Jackson, David — Ceria Therapeutics, INC.
- Study coordinator: Jackson, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.